Grospisk
Grospisk Brand names, Grospisk Analogs
- AMD
- Aldoclor-150
- Aldoclor-250
- Aldomet
- Aldometil
- Aldomin
- Aldoril 15
- Aldoril 25
- Aldoril D30
- Aldoril D50
- Alpha medopa
- Alphamethyldopa
- Apo-Methyldopa
- Bayer 1440 L
- Baypresol
- Becanta
- Dopamet
- Dopamethyperpax
- Dopatec
- Dopegyt
- Grospisk
- Hyperpax
- Hypolag
- L-Methyl Dopa
- Medomet
- Medopa
- Medopal
- Medopren
- Methoplain
- Methyldopa anhydrous
- Methyldopate
- Methyldopate HCL
- Mk. b51
- Novomedopa
- Nu-Medopa
- Presinol
- Presolisin
- Sedometil
- Sembrina
Grospisk Brand Names Mixture
- No information avaliable
Grospisk Chemical_Formula
C56H71N9O23S
Grospisk RX_link
http://www.rxlist.com/cgi/generic4/mycamine.htm
Grospisk fda sheet
Grospisk msds (material safety sheet)
Grospisk Synthesis Reference
No information avaliable
Grospisk Molecular Weight
1270.28 g/mol
Grospisk Melting Point
No information avaliable
Grospisk H2O Solubility
Freely soluble as sodium salt (> 200mg/mL)
Grospisk State
Solid
Grospisk LogP
No information avaliable
Grospisk Dosage Forms
Powder for solution (for injection)
Grospisk Indication
For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Grospisk Pharmacology
Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.
Grospisk Absorption
No information avaliable
Grospisk side effects and Toxicity
Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
Grospisk Patient Information
No information avaliable
Grospisk Organisms Affected
Aspergillis, Candida and other fungi
